Pharmacological therapies including SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists significantly reduced cardiovascular and renal outcomes in patients with diabetes.
Systematic Review
Do pharmacological therapies and lifestyle interventions reduce cardiovascular outcomes in patients with diabetes mellitus?
This systematic review reinforces that combining pharmacological therapies (such as SGLT2 inhibitors and GLP-1 receptor agonists) with lifestyle interventions effectively reduces cardiovascular and renal complications in patients with diabetes.
Diabetes mellitus is a chronic metabolic disorder associated with a two- to four-fold higher risk of cardiovascular morbidity and mortality compared with individuals without diabetes due to complex interactions between metabolic, inflammatory, and vascular pathways. Despite extensive research, uncertainties remain regarding the integrated effects of emerging therapies and persistent cardiovascular risk in diabetic populations. This systematic literature review aimed to evaluate the cardiovascular implications of diabetes mellitus by synthesizing evidence on epidemiology, mechanisms, and clinical outcomes. A structured search was conducted across PubMed, Scopus, Web of Science, and Cochrane Library for studies published between 2015 and 2025, using predefined Boolean search terms, including MeSH terms in PubMed, to identify randomized controlled trials and observational studies reporting cardiovascular outcomes; no review protocol was registered prospectively. Eleven studies were included in the final review after searches were conducted for studies published between 2015 and 2025. Data were extracted and synthesized narratively because clinical and methodological heterogeneity, including differences in populations, interventions, outcomes, study designs, and follow-up durations, precluded formal meta-analysis, and I² assessment. The findings indicate that diabetes significantly increases the risk of major adverse cardiovascular events, heart failure, and mortality, driven by hyperglycemia-induced endothelial dysfunction, inflammation, and atherosclerosis. Pharmacological therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists demonstrated significant reductions in cardiovascular and renal outcomes, while lifestyle interventions contributed to risk reduction. Persistent residual risk highlights incomplete therapeutic control. These findings emphasize the need for integrated and individualized management strategies. This review reinforces the importance of combining pharmacological and lifestyle interventions to effectively reduce cardiovascular complications in diabetes.
Gupta et al. (Mon,) conducted a systematic review in Diabetes mellitus. Pharmacological therapies (SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists) and lifestyle interventions was evaluated on Cardiovascular disease incidence, cardiovascular mortality, heart failure hospitalization, and MACE. Pharmacological therapies including SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists significantly reduced cardiovascular and renal outcomes in patients with diabetes.